Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2003 
         Financial Results on Tuesday, November 11, at 10:00 a.m. EST 
                                        
    NEW YORK, Nov. 7 -- Keryx Biopharmaceuticals, Inc. 
(Nasdaq: KERX; London AIM: KRX) will hold a conference call at 10:00 a.m. EDT 
on Tuesday, November 11, 2003.  Michael S. Weiss, Chairman and Chief Executive 
Officer of the Company, will host the call.  Mr. Weiss will discuss the 
Company's third quarter results for 2003, as well as provide an update on the 
Company's projects, including the recently initiated Phase II/III clinical 
program for KRX-101.  Keryx expects to announce its financial results for this 
period in a press release to be issued on Monday, November 10, 2003.  
    In order to participate in the conference call, please call 1-866-527-8676 
(U.S.), 1-866-485-2399 (Canada), 1-800-227-297 (Israel), 0-800-917-4613 (UK), 
0-800-903-025 (France), 0-800-563-309 (Switzerland), and 0-800-182-6846 
(Germany).  
    The press release announcing our financial results for the third quarter 
of 2003 can be accessed by visiting the Company's website at www.keryx.com 
starting on Tuesday, November 11, 2003. The conference call will also will be 
available for audio replay at www.keryx.com, for a period of 15 days after the 
call.  
 
    ABOUT KERYX BIOPHARMACEUTICALS, INC.  
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceutical company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of life-
threatening diseases, including diabetes and cancer. Keryx is developing KRX-
101 (sulodexide), a novel first-in-class oral heparinoid compound, for the 
treatment of diabetic nephropathy, for which Keryx recently announced the 
initiation of its U.S.-based Phase II/III clinical program. Keryx also has an 
active in-licensing program designed to identify and acquire clinical-stage 
drug candidates. Additionally, Keryx is seeking partners for its KinAce(TM) 
drug discovery technology and related products. Keryx Biopharmaceuticals is 
headquartered in New York City.  
 
     KERYX CONTACT: 
     Ron Bentsur 
     Vice President, Finance & Investor Relations 
     Keryx Biopharmaceuticals, Inc. 
     Tel: 212-531-5965 
     E-mail: ron@keryx.com 
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             11/07/2003 
    /CONTACT: Ron Bentsur, Vice President, Finance & Investor Relations of 
Keryx Biopharmaceuticals, Inc., +1-212-531-5965, ron@keryx.com/ 
    
    /Web site:  http://www.keryx.com / 
    (KERX) 
 
-end-
nnnn



END